Subscribe
Strategy
3 min read

A Pet Chew Brand Is Cutting Prices 20% in a Year Everyone Else Raised Them

BetterBone, a plant-based dog-chew brand made on parent Blue Standard's material, told the trade it will cut prices across its line by nearly 20% while holding or improving distributor margins, crediting expanded production in Austria and Hungary and patent-pending processes. The brand discloses no financials, so the margin and efficiency claims rest on its word. The durable operator question is whether a cost-funded cut reaches shelves and holds.

Written by
The Underbite
Published on
June 30, 2026
A Pet Chew Brand Is Cutting Prices 20% in a Year Everyone Else Raised Them

Most pet brands met tariffs and input inflation with higher shelf prices over the past two years. A small plant-based dog-chew maker is doing the opposite, telling retailers and distributors it will drop prices across its line by nearly 20% and claiming it can do so while holding, or improving, the margin its partners earn. The claim is the interesting part, and it rests entirely on where and how the product gets made.

The price move is really a manufacturing story

BetterBone, the chew brand built on parent company Blue Standard's plant-based material, ties the cut to expanded production across its European network and a set of patent-pending processes it says lowered unit costs. The company points to added capacity in Austria and Hungary, layered onto existing EU manufacturing, as the source of the efficiency. The pitch to the trade is that scale and process, not a margin giveaway, paid for the lower price.

That framing matters because a price cut funded by promotion is a temporary discount, while one funded by lower cost of goods is a durable repositioning. The company is asserting the second. It says distributor margins stay intact or improve even at the lower price, which is the only version of a cut that a wholesale partner has reason to welcome rather than fear.

What is not on the table is any disclosed financial proof. The brand is privately held and shares no revenue, volume, or funding figures, so the margin and efficiency claims cannot be checked against numbers. Operators weighing the news are taking the manufacturing story on the company's word for now.

Why a 20% cut should register with operators

Pricing is the loudest signal a brand sends, and a double-digit cut in a year of broad increases is a deliberate land grab for the value-conscious end of the premium chew shelf. The durable-chew category is crowded with nylon and rubber incumbents and a growing field of natural and plant-based challengers, and price is one of the few levers that moves a shopper between near-identical products. A brand that can hold quality while undercutting on price is betting that velocity at the lower number beats margin at the higher one.

The reshoring angle is the quieter signal. While much of the industry has spent two years exposed to tariff swings on Asian-made goods, a brand manufacturing inside the EU is making a case that proximity and regulatory standards are now a cost story, not just a marketing one. Whether that holds depends on input and freight math the company has not shown.

What to watch before believing the thesis

The release pairs the price news with an August brand refresh, new packaging, and merchandising assets, which is the part operators can safely discount as ordinary marketing. The substance is whether the lower price actually reaches shelves and holds. Watch whether distributors pass the cut through or pocket it, whether the improved-margin claim survives contact with real wholesale terms, and whether a small brand can fund a 20% cut without starving the service and replacement programs it is also promising to expand. A price cut is easy to announce and hard to sustain, and the next two seasons of availability and reorder data will say which one this is.

Source: BetterBone pricing announcement via PETS+; company submission via The Underbite press form

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
Vetspire Splits From Thrive, Lands a Battery Ventures Backing
Funding & M&A
4 min read

Vetspire Splits From Thrive, Lands a Battery Ventures Backing

Vetspire has spun out of Thrive Pet Healthcare's orbit with a growth investment from Battery Ventures and a new CEO, Zachary Seely. The AI-powered practice management platform, used by more than 800 veterinary hospitals and clinics, will operate independently while Thrive remains a customer. The deal tests whether AI-native vet software can draw institutional capital without a strategic parent underwriting it.

Read article
Read article
PetMeds Revenue Falls 20% as Takeover Fight Drags On
Earnings
6 min read

PetMeds Revenue Falls 20% as Takeover Fight Drags On

PetMeds' first-quarter revenue fell 19.9% to $41.0 million and cash reserves dropped to $13.1 million, even as the company narrowed its net loss to $6.1 million from $34.2 million a year earlier. The results land as an unsolicited $3-a-share buyout offer from SilverCape Investments remains on the table and a $37 million sale-leaseback of its headquarters awaits closing.

Read article
Read article
FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North
Regulatory
4 min read

FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North

The FDA granted Zoetis an emergency use authorization for Simparica Trio to treat New World screwworm in dogs, the first product cleared specifically for the threat. Texas has already begun requiring treatment before dogs cross certain lines, putting boarding facilities, transporters, and border-state vet practices under a new compliance mandate.

Read article
View all articles